Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sher Karki

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|October 3, 2008
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemiaHolly M Horton, Matthew J Bernett, Erik Pong, et al.
Journal of Molecular Biology|January 5, 2010
Engineering fully human monoclonal antibodies from murine variable regionsMatthew J Bernett, Sher Karki, Gregory L Moore, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
Engineered antibody Fc variants with enhanced effector functionGreg A Lazar, Wei Dang, Sher Karki, et al.
Blood|January 17, 2012
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector functionYu-Tzu Tai, Holly M Horton, Sun-Young Kong, et al.
Cancer Research|February 1, 2018
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug ConjugatesHui Zhao, John Atkinson, Sara Gulesserian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell CarcinomaFernando Doñate, Arthur Raitano, Kendall Morrison, et al.
Molecular Cancer Therapeutics|May 3, 2015
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AMLDaniel S Pereira, Claudia I Guevara, Liqing Jin, et al.
Cancer Research|March 26, 2016
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer ModelsPia M Challita-Eid, Daulet Satpayev, Peng Yang, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|October 3, 2008
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemiaHolly M Horton, Matthew J Bernett, Erik Pong, et al.
Journal of Molecular Biology|January 5, 2010
Engineering fully human monoclonal antibodies from murine variable regionsMatthew J Bernett, Sher Karki, Gregory L Moore, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
Engineered antibody Fc variants with enhanced effector functionGreg A Lazar, Wei Dang, Sher Karki, et al.
Blood|January 17, 2012
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector functionYu-Tzu Tai, Holly M Horton, Sun-Young Kong, et al.
Cancer Research|February 1, 2018
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug ConjugatesHui Zhao, John Atkinson, Sara Gulesserian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2015
AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell CarcinomaFernando Doñate, Arthur Raitano, Kendall Morrison, et al.
Molecular Cancer Therapeutics|May 3, 2015
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AMLDaniel S Pereira, Claudia I Guevara, Liqing Jin, et al.
Cancer Research|March 26, 2016
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer ModelsPia M Challita-Eid, Daulet Satpayev, Peng Yang, et al.
Pageof 2